Online inquiry

IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13386MR)

This product GTTS-WQ13386MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PRLR gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000949.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5618
UniProt ID P16471
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13386MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1200MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ9709MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ1789MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-402
GTTS-WQ6896MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA E-6011
GTTS-WQ2632MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 592
GTTS-WQ5552MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ15866MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ14740MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SGN-19A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW